DocWire News Editors

DocwireNews

Resistance to BRAF inhibition in vitro is mediated by the two distinct mechanisms of clonal outgrowth of genetically distinct resistant clones, and of transcriptional rewiring, according to a study presented at the 17th International Myeloma Workshop.In this study, researchers modeled resistance to dabrafenib in vitro in two BRAF-mutated multiple myeloma (MM) cell lines -(MMCL) U266 (K601N-mut) and DP6 (BRAFV600E-mut). Subsequently, they performed low-pass whole genome sequencing (LPWGS), RNA sequencing, ChIP sequencing and immunoblotting for genomic, transcriptomic, epigenomic and molecular characterization. They also used CRISPR/Cas9 technology for genome editing to assess functional validation.According to the results of the study, modeling of dabrafenib resistance in vitro exhibited an initial decline of cell numbers, and subsequently a plateau phase followed by a gradual outgrowth of resistant cells, after 80 days of treatment. The researchers observed that exposure of BRAF-mut MMCL to dabrafenib led to initial downregulation of pERK and pMEK. Moreover, at later timepoints, the results revealed the upregulation of pERK and pMEK, indicating that re-activation of the ERK/MEK pathway overcomes BRAF inhibition. The authors wrote that this outgrowth &ldquo;was associated with highly distinct copy number profiles in each resistant clone. This implies clonal selection with outgrowth of genetically resistant clones as one mechanism of drug resistance in MM.&rdquo;A second step of the study found that BRAF inhibition of BRAF-mut MMCL prompts changes of the transcriptional circuitry independent from clonal outgrowth of genetically resistant clones. The researchers noted the transcriptional changes were highly homogenous, occurred as early as a week after treatment, and was correlated with dedifferentiation of MMCL into a more immature B lymphocytic phenotype, which was linked with a greater mRNA expression and an upregulation of pathway genes.The authors wrote in their conclusion that transcriptional rewiring that leads to activation of alternative pathways is characterized by a &ldquo;de-differentiated B-cell phenotype and upregulation of PI3K and CD28/CD86 signaling.&rdquo;They added that these concepts &ldquo;may provide a framework for revealing therapeutic vulnerabilities and to overcome drug resistance mediated by genetic heterogeneity in MM.&rdquo;Waldschmidt J. Determining Resistance Mechanisms in BRAF-Mutated Multiple Myeloma. Presented at the 17th International Myeloma Workshop; September 12-15, 2019; Boston, MA.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Determining Resistance Mechanisms in BRAF-Mutated Multiple Myeloma

International Myeloma Workshop 2019

Resistance to BRAF inhibition in vitro is mediated by the two distinct mechanisms of clonal outgrowth of genetically distinct resistant clones, and of transcriptional rewiring

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe